SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is facing intense volatility as traders debate whether it can decisively break through the 1,800 resistance level or if it remains trapped in a bearish consolidation pattern. The community is sharply divided, with bulls pointing to potential regulatory clarity and institutional adoption as catalysts for a rally, while bears warn of further downside and structural weakness.

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Vertex Pharmaceuticals, Inc.

Vertex Pharmaceuticals is currently attracting investor attention as the market evaluates its aggressive expansion into kidney disease and rare endocrine disorders alongside its established cystic fibrosis franchise. Community discussions are heavily focused on the company's recent acquisition of Crinetics Pharmaceuticals and the long-term outlook for its diverse drug pipeline.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending as investors digest significant institutional accumulation and aggressive open-market share purchases by CEO Kevin Tang, fueling widespread speculation about a potential near-term buyout or merger. While the community is actively debating the company's long-term pipeline and patent position, sentiment remains dominated by frustration over past leadership and high-stakes anticipation for a major strategic catalyst.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

The XRP community is actively discussing rumors of potential Clarity Act legislation and ongoing Japanese institutional adoption, though price stagnation remains a primary source of frustration. Investors are divided between long-term accumulation strategies based on XRP's utility and deep skepticism driven by lackluster performance compared to other major assets.

|The Artificial Superintelligence (ASI) Alliance is the world’s largest open-source initiative dedicated to decentralized Artificial General Intelligence (AGI). Formed in April 2024, the ASI Alliance unites SingularityNET, Fetch.ai, and Ocean Protocol, with CUDOS joining as a network member shortly after. The ASI Alliance was established through a community-approved tokenomic merger—combining $AGIX, $FET, and $OCEAN into a single token: $FET. This unified token underpins a collaborative framework designed to scale open-source AI and stand as the largest open-sourced, independent entity in AI research and development. The Alliance is committed to accelerating the advancement of decentralized Artificial General Intelligence (AGI) and, ultimately, Artificial Superintelligence (ASI). It provides a robust, open-source innovation stack, empowering developers, enterprises, and researchers globally to build ethical, scalable, and groundbreaking AI solutions. This ensures that advanced intelligence remains a shared, accessible resource, fostering innovation beyond centralized systems and promoting a future where AI benefits all.

Fetch.ai

Fetch.ai (FET) remains a focal point for the AI-crypto community as traders weigh its established infrastructure against broader market volatility and Bitcoin-driven price action. Sentiment is split between those aggressively dollar-cost averaging in anticipation of long-term utility gains and skeptics questioning the token's recent performance compared to newer AI-themed assets.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Abbvie Inc

AbbVie Inc. is trending as investors digest news of a pending $10.9 billion acquisition of Apogee Therapeutics, alongside active discussions regarding the company's patent cliffs and strategic pivots into the obesity and immunology markets. Community members are closely debating the potential impact of these moves on the stock's long-term growth and its competitive position against rivals in the pharmaceutical sector.

iShares Bitcoin Trust ETF (The) - iShares Bitcoin Trust Beneficial Interest

iShares Bitcoin ETF

IBIT is trending as Bitcoin faces continued selling pressure, sparking active community debate over the asset's long-term viability amid institutional outflows and shifting regulatory clarity. Traders are closely monitoring key technical support levels and high-volume options activity, while many discuss the decoupling of related proxies like MicroStrategy from spot price performance.

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

CrowdStrike is seeing significant volatility following a post-earnings selloff, as investors react to a quarterly performance that met expectations but failed to exceed the elevated bar set by the stock's recent rapid rally. Despite the downward pressure, the community is heavily focused on the company's newly announced 4-for-1 stock split and ongoing institutional confidence in its long-term AI-driven cybersecurity leadership.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending as investors debate management's operational transparency and the delayed publication of corrected asset valuations, while simultaneously monitoring potential geopolitical catalysts involving Greenland's strategic importance to the Western rare earth supply chain. Community discussion remains heavily polarized between long-term bulls highlighting the Tanbreez project's massive potential and skeptics criticizing share dilution, lack of progress on feasibility studies, and the CEO's communication style.

Select Sector SPDR Trust (The) - State Street Financial Select Sector SPDR ETF

Financial Select Sector SPDR Fund

The Financial Select Sector SPDR Fund ($XLF) is trending as institutional investors rotate into the sector, with community analysis highlighting a bullish breakout from key support zones and heavy accumulation ahead of upcoming earnings cycles. Traders are closely watching for signs that this rotation can sustain the momentum and clear overhead resistance, despite some conflicting macro narratives regarding the durability of recent gains.

statis crypto Watchlist

Bitcoin

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

YD Bio (NASDAQ:YDES) Shares Up 2.8% - Here's Why

YD Bio (NASDAQ:YDES) Shares Up 2.8% - Should You Buy...

YD Bio (NASDAQ:YDES) Shares Gap Up - What's Next?

YD Bio (NASDAQ:YDES) Shares Gap Up - Here's What Happened...

YD Bio (NASDAQ:YDES) Trading Down 3.5% - Here's What Happened

YD Bio (NASDAQ:YDES) Trading Down 3.5% - Time to Sell...

YD Bio (NASDAQ:YDES) Trading 12.5% Higher - Here's Why

YD Bio (NASDAQ:YDES) Trading 12.5% Higher - Here's Why...

Apogee Therapeutics, Tower Semiconductor, Norwegian Cruise Line And Other Big Stocks Moving Higher On Thursday

Stocks fall, Nasdaq drops 200 points. Apogee Therapeutics (APGE) rises 19.4% on positive trial data. Satellogic (SATL), YD Bio (YDES), AXT Inc (AXTI) also see gains.read more...

YD Bio (NASDAQ:YDES) Sets New 52-Week Low - Here's What Happened

YD Bio (NASDAQ:YDES) Hits New 52-Week Low - Should You Sell...

YD Bio (NASDAQ:YDES) Stock Price Down 5.6% - Here's Why

YD Bio (NASDAQ:YDES) Trading Down 5.6% - Here's Why...

YD Bio (NASDAQ:YDES) Trading 7.9% Higher - Still a Buy?

YD Bio (NASDAQ:YDES) Stock Price Up 7.9% - What's Next...

YD Bio (NASDAQ:YDES) Shares Gap Up - Time to Buy?

YD Bio (NASDAQ:YDES) Shares Gap Up - Time to Buy...

YD Bio (NASDAQ:YDES) Stock Price Down 9.1% - Here's Why

YD Bio (NASDAQ:YDES) Stock Price Down 9.1% - Here's What Happened...

YD Bio Ltd. is a biotechnology company building an integrated healthcare platform across regulated diagnostics, clinical services, and commercial healthcare markets. It operates DNA methylation–based oncology testing programs under an LDT-first strategy and provides compliant life science distribution and clinical trial supply chain services to pharmaceutical and biotechnology partners. The company’s offerings include cancer detection products, regenerative ophthalmology solutions, and exosome-based technologies. YD Bio was founded on February 6, 2024 and is headquartered in Taipei, Taiwan.

YD Bio Ltd.

YD Bio Stock Rises On Entry Into US Eye Care Segment

Equity

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$2.23
Prev Close	$2.14
Open	$2.04
Dividend Yield	0.00%
50-Day Moving Average	$3.61
Beta	0.21
Avg. Volume	61,862.44
PE Ratio	-2.26

52-Week High	$25.00
52-Week Low	$1.70
Market Capitalization	$157.86M
EPS (Annual)	-$0.1246
Price to Book	-0.47
Revenue Per Employee	$39,787.80

Feed

News

Sentiment

Fundamentals

Info

YDESYD Bio Ltd.

Latest YDES News